Annual SG&A
$13.04 M
-$138.00 K-1.05%
31 December 2023
Summary:
Cardiff Oncology annual selling, general & administrative expenses is currently $13.04 million, with the most recent change of -$138.00 thousand (-1.05%) on 31 December 2023. During the last 3 years, it has risen by +$4.83 million (+58.73%). CRDF annual SG&A is now -43.29% below its all-time high of $23.00 million, reached on 31 December 2016.CRDF Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$3.13 M
-$89.00 K-2.77%
30 September 2024
Summary:
Cardiff Oncology quarterly selling, general & administrative expenses is currently $3.13 million, with the most recent change of -$89.00 thousand (-2.77%) on 30 September 2024. Over the past year, it has increased by +$187.00 thousand (+6.36%). CRDF quarterly SG&A is now -55.73% below its all-time high of $7.06 million, reached on 31 March 2016.CRDF Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.42 B
-$42.19 M-3.06%
30 September 2024
Summary:
Cardiff Oncology TTM selling, general & administrative expenses is currently -$1.42 billion, with the most recent change of -$42.19 million (-3.06%) on 30 September 2024. Over the past year, it has dropped by -$1.43 billion (-10709.35%). CRDF TTM SG&A is now -3159.82% below its all-time high of $23.00 million, reached on 31 December 2016.CRDF TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRDF Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -1.1% | +6.4% | -10000.0% |
| 3 y3 years | +58.7% | +6.7% | -10000.0% |
| 5 y5 years | +62.9% | +117.0% | -10000.0% |
CRDF Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -1.1% | +58.7% | -27.2% | +14.7% | -47.7% | at low |
| 5 y | 5 years | -1.1% | +126.4% | -27.2% | +117.0% | -79.1% | at low |
| alltime | all time | -43.3% | +567.5% | -55.7% | +167.4% | -3159.8% | at low |
Cardiff Oncology Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $3.13 M(-2.8%) | $12.20 M(+1.6%) |
| June 2024 | - | $3.21 M(+2.7%) | $12.01 M(-8.3%) |
| Mar 2024 | - | $3.13 M(+14.9%) | $13.09 M(+0.4%) |
| Dec 2023 | $13.04 M(-1.0%) | $2.73 M(-7.3%) | $13.04 M(-2.6%) |
| Sept 2023 | - | $2.94 M(-31.6%) | $13.40 M(-1.0%) |
| June 2023 | - | $4.30 M(+39.3%) | $13.53 M(+9.8%) |
| Mar 2023 | - | $3.08 M(+0.2%) | $12.32 M(-6.5%) |
| Dec 2022 | $13.18 M(+11.3%) | $3.08 M(+0.0%) | $13.18 M(-5.4%) |
| Sept 2022 | - | $3.08 M(-0.3%) | $13.94 M(+1.1%) |
| June 2022 | - | $3.09 M(-21.7%) | $13.79 M(+1.8%) |
| Mar 2022 | - | $3.94 M(+2.7%) | $13.54 M(+14.4%) |
| Dec 2021 | $11.84 M(+44.1%) | $3.83 M(+30.9%) | $11.84 M(+3.7%) |
| Sept 2021 | - | $2.93 M(+3.2%) | $11.42 M(+12.7%) |
| June 2021 | - | $2.84 M(+27.0%) | $10.13 M(+13.0%) |
| Mar 2021 | - | $2.23 M(-34.6%) | $8.96 M(+9.1%) |
| Dec 2020 | $8.22 M(+42.6%) | $3.42 M(+107.8%) | $8.22 M(+30.1%) |
| Sept 2020 | - | $1.64 M(-1.5%) | $6.32 M(+3.3%) |
| June 2020 | - | $1.67 M(+12.3%) | $6.11 M(+4.1%) |
| Mar 2020 | - | $1.49 M(-2.1%) | $5.87 M(+1.9%) |
| Dec 2019 | $5.76 M(-28.0%) | $1.52 M(+5.4%) | $5.76 M(-1565.9%) |
| Sept 2019 | - | $1.44 M(+0.9%) | -$393.00 K(-126.3%) |
| June 2019 | - | $1.43 M(+3.8%) | $1.50 M(-32.6%) |
| Mar 2019 | - | $1.38 M(-129.7%) | $2.22 M(-33.7%) |
| Dec 2018 | $8.01 M(-43.8%) | -$4.64 M(-239.2%) | $3.35 M(-66.0%) |
| Sept 2018 | - | $3.33 M(+54.8%) | $9.86 M(-7.1%) |
| June 2018 | - | $2.15 M(-14.1%) | $10.61 M(-19.2%) |
| Mar 2018 | - | $2.50 M(+33.6%) | $13.13 M(-7.7%) |
| Dec 2017 | $14.23 M | $1.87 M(-54.0%) | $14.23 M(-16.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2017 | - | $4.08 M(-12.7%) | $17.05 M(-8.4%) |
| June 2017 | - | $4.67 M(+29.7%) | $18.62 M(-4.7%) |
| Mar 2017 | - | $3.60 M(-23.1%) | $19.54 M(-15.0%) |
| Dec 2016 | $23.00 M(+60.1%) | $4.69 M(-17.1%) | $23.00 M(+2.6%) |
| Sept 2016 | - | $5.65 M(+1.0%) | $22.41 M(+9.3%) |
| June 2016 | - | $5.60 M(-20.7%) | $20.50 M(+8.9%) |
| Mar 2016 | - | $7.06 M(+72.3%) | $18.82 M(+31.1%) |
| Dec 2015 | $14.36 M(+68.1%) | $4.10 M(+9.4%) | $14.36 M(+10.7%) |
| Sept 2015 | - | $3.75 M(-4.4%) | $12.97 M(+15.5%) |
| June 2015 | - | $3.92 M(+50.6%) | $11.23 M(+21.9%) |
| Mar 2015 | - | $2.60 M(-4.0%) | $9.22 M(+7.9%) |
| Dec 2014 | $8.54 M(+22.0%) | $2.71 M(+35.0%) | $8.55 M(+14.8%) |
| Sept 2014 | - | $2.01 M(+5.6%) | $7.45 M(-2.6%) |
| June 2014 | - | $1.90 M(-1.5%) | $7.64 M(+5.8%) |
| Mar 2014 | - | $1.93 M(+19.7%) | $7.22 M(+3.2%) |
| Dec 2013 | $7.00 M(+107.2%) | $1.61 M(-27.0%) | $7.00 M(+9.5%) |
| Sept 2013 | - | $2.21 M(+49.1%) | $6.40 M(+29.8%) |
| June 2013 | - | $1.48 M(-13.3%) | $4.93 M(+15.7%) |
| Mar 2013 | - | $1.71 M(+70.1%) | $4.26 M(+26.0%) |
| Dec 2012 | $3.38 M(+45.4%) | $1.00 M(+35.8%) | $3.38 M(+13.5%) |
| Sept 2012 | - | $739.00 K(-8.8%) | $2.98 M(+5.4%) |
| June 2012 | - | $809.90 K(-2.1%) | $2.83 M(+8.7%) |
| Mar 2012 | - | $827.00 K(+37.3%) | $2.60 M(+11.9%) |
| Dec 2011 | $2.32 M(+18.9%) | $602.50 K(+2.8%) | $2.32 M(+35.0%) |
| Sept 2011 | - | $586.20 K(+0.4%) | $1.72 M(+51.6%) |
| June 2011 | - | $584.00 K(+6.0%) | $1.14 M(+106.0%) |
| Mar 2011 | - | $551.00 K | $551.00 K |
| Dec 2010 | $1.95 M | - | - |
FAQ
- What is Cardiff Oncology annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Cardiff Oncology?
- What is Cardiff Oncology annual SG&A year-on-year change?
- What is Cardiff Oncology quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Cardiff Oncology?
- What is Cardiff Oncology quarterly SG&A year-on-year change?
- What is Cardiff Oncology TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Cardiff Oncology?
- What is Cardiff Oncology TTM SG&A year-on-year change?
What is Cardiff Oncology annual selling, general & administrative expenses?
The current annual SG&A of CRDF is $13.04 M
What is the all time high annual SG&A for Cardiff Oncology?
Cardiff Oncology all-time high annual selling, general & administrative expenses is $23.00 M
What is Cardiff Oncology annual SG&A year-on-year change?
Over the past year, CRDF annual selling, general & administrative expenses has changed by -$138.00 K (-1.05%)
What is Cardiff Oncology quarterly selling, general & administrative expenses?
The current quarterly SG&A of CRDF is $3.13 M
What is the all time high quarterly SG&A for Cardiff Oncology?
Cardiff Oncology all-time high quarterly selling, general & administrative expenses is $7.06 M
What is Cardiff Oncology quarterly SG&A year-on-year change?
Over the past year, CRDF quarterly selling, general & administrative expenses has changed by +$187.00 K (+6.36%)
What is Cardiff Oncology TTM selling, general & administrative expenses?
The current TTM SG&A of CRDF is -$1.42 B
What is the all time high TTM SG&A for Cardiff Oncology?
Cardiff Oncology all-time high TTM selling, general & administrative expenses is $23.00 M
What is Cardiff Oncology TTM SG&A year-on-year change?
Over the past year, CRDF TTM selling, general & administrative expenses has changed by -$1.43 B (-10709.35%)